Treatment of patients with type 2 diabetes (T2D) with insulin or sulphonylurea therapy in an intensive therapeutic regime may lead to hypoglycemia, which may result in loss of consciousness, seizure, coma and even death [1]. The gene discussed is INS; the disease is type 2 diabetes mellitus.